Head-to-head evidence
AADvac1 vs Etalanetug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
AADvac1
Developed by Axon Neuroscience
NCT02579252 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 208 participants, with safety as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: August 2028 · NCT07167966 (registry estimate)
Etalanetug
Developed by Eisai
NCT04971733 · Phase 1/2 · completed
The study treated 8 participants with E2814 in open-label, single-arm cohorts without randomization, blinding, or a comparator, and its biomarker primary endpoint was not a controlled clinical comparison. Because the named drug is Etalanetug but the trial intervention was E2814, these results are not direct evidence for Etalanetug.
Next expected readout: December 2026 · NCT06602258 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AADvac1's landscape · Etalanetug's landscape